Aisling Capital

Aisling Capital is a New York-based private investment firm founded in 2000 that specialises in backing companies in the healthcare and life sciences sectors, including biopharmaceuticals, medical technologies, diagnostics and related services. The firm has raised over $1.8 billion in institutional capital and focuses on mid-market and growth-oriented opportunities where it can support product development and commercialisation. Aisling participates in both private and, at times, public financings and is known for active sector expertise in advancing therapies and technologies from clinical stages toward market impact. Its portfolio includes a range of companies across biotech and healthcare services in the United States and select international markets. The firm’s strategy emphasises deep industry knowledge alongside investment capital to help portfolio companies achieve clinical, regulatory and commercial milestones.